| République de Corée | Turquie | Espagne | |
| Chirurgie du sarcome | de $7,600 | de $10,000 | de $31,111 |
| Chimiothérapie pour le cancer du sein | de $19,200 | de $1,200 | de $3,500 |
| Traitement complexe du sarcome d'Ewing | - | de $30,000 | de $35,000 |
| Résection osseuse | - | de $8,000 | de $20,000 |
| Radiothérapie pour les sarcomes | - | de $3,250 | de $8,000 |
Bookimed ne rajoute pas de frais pour les traitements de Sarcome d'Ewing. Les tarifs proviennent des listes de prix officielles des cliniques. Vous payez directement à la clinique pour votre traitement à votre arrivée dans le pays.
Bookimed s'engage pour votre sécurité. Nous ne travaillons qu'avec des établissements médicaux qui respectent des normes internationales élevées dans le traitement de Sarcome d'Ewing et qui possèdent les licences nécessaires pour accueillir des patients internationaux dans le monde entier.
Bookimed offre une assistance experte gratuite. Un coordinateur médical personnel vous accompagne avant, pendant et après votre traitement, en résolvant tous les problèmes. Vous n'êtes jamais seul dans votre parcours de traitement de Sarcome d'Ewing.
Samsung Medical Center, Seoul National University Hospital, and Asan Medical Center are the premier institutions for Ewing's sarcoma in Korea. These centers offer integrated multidisciplinary care. They utilize advanced PET-CT diagnostics and limb-sparing surgical techniques. Specialized sarcoma teams ensure precise treatment for rare bone tumors.
Bookimed Expert Insight: While hospital reputation matters, patient data highlights volume as the key quality indicator. Asan Medical Center performs over 65,000 surgeries annually. This high frequency with complex procedures typically correlates with better outcomes for rare cancers. Specialized teams at these major Seoul centers handle the highest density of rare sarcoma cases nationwide.
Patient Consensus: Patients emphasize choosing large tertiary centers over general hospitals for this specific diagnosis. They strongly recommend bringing original biopsy slides and imaging for a second pathology review.
The 5-year survival rate for Ewing's sarcoma in South Korea is approximately 52% overall. Pediatric patients show better outcomes with a 75% survival rate. Adolescents and young adults maintain a 51% survival rate. Success depends on the tumor stage and receiving multidisciplinary care at JCI or KOIHA-accredited centers.
Bookimed Expert Insight: While national averages hover around 52%, high-volume centers like Asan Medical Center perform over 65,000 operations annually. These major institutions often handle more complex cases than smaller facilities. Patients should look for centers with Newsweek-ranked oncology departments. These hospitals typically have dedicated sarcoma teams to manage rare bone cancers more effectively.
Patient Consensus: Patients emphasize finding a hospital with a specific sarcoma team rather than general oncology. They note that survival depends heavily on whether surgeons can remove the tumor cleanly and whether the cancer has spread at diagnosis.
Ewing's sarcoma treatment in Korea utilizes a multidisciplinary approach combining high-dose chemotherapy with localized surgery or advanced radiation. Major Seoul-based tertiary centers utilize Newsweek-ranked oncology departments. These facilities provide systemic drug protocols alongside digital surgical systems to ensure precise tumor removal and limb preservation.
Bookimed Expert Insight: Korea's leading tertiary hospitals manage massive patient volumes, with Samsung Medical Center seeing over 2,000,000 patients annually. This high throughput is a direct quality signal for rare cancers like Ewing's sarcoma. It ensures that surgical teams maintain peak proficiency in complex resections. Choosing these high-volume centers in Seoul provides access to multidisciplinary tumor boards that meet Newsweek's global excellence standards.
Patient Consensus: Patients emphasize that receiving care at a major university hospital is vital due to the disease's complexity. They note that managing chemotherapy side effects requires strong supportive care and experienced nursing teams.
Proton beam therapy is available for Ewing's sarcoma in Korea at specialized oncology centers in Seoul. Facilities like Samsung Medical Center utilize this advanced radiation to treat tumors while protecting healthy organs. It is particularly valuable for pediatric cases and tumors located near sensitive structures.
Bookimed Expert Insight: While several Seoul hospitals treat sarcoma, Samsung Medical Center is a standout choice because it combines proton therapy with nearly 2,000,000 annual patient visits. This massive patient volume ensures surgeons and radiologists have deep experience with rare bone tumors. If you are looking for advanced radiotherapy, focusing on centers with verified JCI-level accreditations in Seoul provides the highest safety standards.
Patient Consensus: Patients note that proton therapy is a specialized option often requiring specific referrals. They emphasize checking if tumor location warrants radiation sparing before arranging travel to Seoul centers.
Seeking a second opinion for Ewing sarcoma in South Korea is standard practice for confirming diagnostic accuracy and treatment sequencing. Major Seoul-based tertiary centers utilize multidisciplinary tumor boards and specialized pathology reviews to ensure limb-sparing surgery options and precise radiation protocols are prioritized for patients.
Bookimed Expert Insight: Clinical volume is the strongest indicator of success for rare bone cancers in Seoul. Asan Medical Center treats over 11,000 outpatients daily. Specialized oncology centers like Samsung Medical Center provide integrated care. Choosing a high-volume facility ensures your case reaches a dedicated sarcoma board rather than a general surgeon.
Patient Consensus: Patients emphasize that initial treatment plans often vary significantly between hospitals regarding surgery versus radiation. It is vital to bring a complete packet including pathology blocks and imaging discs to avoid any diagnostic delays.